Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

275
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
275
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents01:18

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

194
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
194
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

301
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
301
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

229
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
229
Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents01:20

Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents

304
Diarrhea is characterized by the occurrence of frequent, watery bowel movements. Various factors can trigger diarrhea, including viral or bacterial infections, foodborne illnesses, side effects from certain medications, and underlying digestive disorders. If not adequately managed, diarrhea can lead to complications such as dehydration, electrolyte imbalances, and nutrient deficiencies. Severe diarrhea can lead to significant weight loss, malnutrition, and weakened immune function.
Adsorbents...
304
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

174
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
174

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Distinct cochlear cell types associated with genetic susceptibility to sensory and metabolic hearing loss in older adults from the CLSA.

bioRxiv : the preprint server for biology·2026
Same author

Short tandem repeats significantly contribute to the genetic architecture of metabolic and sensory age-related hearing loss phenotypes.

medRxiv : the preprint server for health sciences·2026
Same author

Basic Science and Pathogenesis.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Large-scale audiometric phenotyping identifies distinct genes and pathways involved in hearing loss subtypes.

Communications biology·2025
Same author

Comparison of <i>Chlamydia pneumoniae</i>-specific T Effector Memory Lymphocytes in Asthmatic and Non-Asthmatic Adults.

Annals of clinical and laboratory science·2025
Same author

Comparative efficacy of cementless bipolar hemiarthroplasty and proximal femoral nail anti-rotation in unstable intertrochanteric fractures: A meta-analysis.

World journal of orthopedics·2025
Same journal

A Retrospective Analysis of Cardiac Anatomy in Patients Undergoing the Fontan Operation.

Cureus·2026
Same journal

A Narrative Review of the Potential Impact of Next-Generation Tobacco and Nicotine Products on Cardiovascular Health.

Cureus·2026
Same journal

A Prospective Comparative Study for the Evaluation of Digital Learning as an Academic Tool for MBBS Phase III Students.

Cureus·2026
Same journal

Crossing the Septum: May-Thurner Syndrome and Patent Foramen Ovale as a Dual Mechanism for Recurrent Ischemic Stroke.

Cureus·2026
Same journal

Physical Restraint Practices, Attitudes, and Ethical Perceptions Among Intensive Care Unit (ICU) Doctors and Nurses in Morocco: A Cross-Sectional Survey Highlighting the Training-Use Paradox.

Cureus·2026
Same journal

Reversible Rapidly Progressive Dementia Due to Cerebral Amyloid Angiopathy.

Cureus·2026
See all related articles

Related Experiment Video

Updated: Aug 29, 2025

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
08:53

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Published on: July 27, 2022

906

Do Probiotics Prevent Clostridium difficile-Associated Diarrhea?

Afrah Al Sharaby1, Tahani M Abugoukh2, Wefag Ahmed3

  • 1Internal Medicine, Michigan State University, San Francisco, USA.

Cureus
|September 8, 2022
PubMed
Summary
This summary is machine-generated.

Probiotics show promise in preventing Clostridium difficile-associated diarrhea (CDAD), offering a safe and well-tolerated approach. Further research is needed to establish optimal probiotic use for this common gastrointestinal infection.

Keywords:
clostridium difficilediarrheaefficacypreventionprobiotics

More Related Videos

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

27.2K
Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
06:51

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

12.7K

Related Experiment Videos

Last Updated: Aug 29, 2025

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
08:53

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Published on: July 27, 2022

906
Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

27.2K
Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
06:51

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

12.7K

Area of Science:

  • Gastroenterology
  • Microbiology
  • Infectious Diseases

Background:

  • Clostridium difficile is a leading cause of antibiotic-associated diarrhea.
  • Probiotics are microorganisms studied for preventing and treating Clostridium difficile-associated diarrhea (CDAD).
  • Probiotics exert beneficial effects by suppressing harmful gut bacteria.

Purpose of the Study:

  • To evaluate the efficacy and safety of probiotics in preventing CDAD.
  • To synthesize current evidence on probiotic use for CDAD prevention.

Main Methods:

  • A literature review was conducted.
  • Searched PubMed and Google Scholar databases for relevant articles.
  • Included 13 papers with diverse study designs based on eligibility criteria.

Main Results:

  • Probiotics demonstrated promising effects in preventing CDAD.
  • Probiotic interventions were found to be safe and well-tolerated.
  • Evidence suggests a beneficial role for probiotics in CDAD prevention.

Conclusions:

  • Probiotics are a potentially effective and safe strategy for CDAD prevention.
  • Further large-scale randomized clinical trials are necessary.
  • Optimal probiotic dosage and treatment duration require further investigation.